GlassScriptPhysician profile
Bruce W Ricker
NPI 1851441760
$2,895.03
in general payments reported to CMS, 2019-2025
32 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $325 · 2021: $516 · 2022: $271 · 2023: $542 · 2024: $246 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $387.72 | 2019-2025 | |
| Novo Nordisk INC | $353.72 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $301.82 | 2019-2025 | |
| Amgen INC. | $299.99 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.47 | 2019-2025 | Jardiance, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $166.78 | 2019-2025 | |
| Mylan Specialty L.P. | $142.96 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $125.51 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $120.44 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $110.48 | 2019-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $66.83 | 2020-2023 | Shingrix |
| Sanofi-Aventis U.S. LLC | $66.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.34 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Janssen Pharmaceuticals, INC | $49.25 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $48.73 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43.18 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.69 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $32.94 | 2022 | |
| Verona Pharma, INC. | $28.33 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $26.47 | 2019-2021 | |
| Amarin Pharma, INC. | $25.41 | 2021 | |
| Abiomed | $20.42 | 2025 | |
| Axsome Therapeutics, INC. | $16.43 | 2023 | Auvelity |
| Lundbeck LLC | $16.39 | 2024 | Rexulti |
| Cranial Technologies, INC | $15.07 | 2025 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.02 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.36 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $14.27 | 2020 | |
| Sobi, INC | $14.18 | 2023 | |
| Viatris Specialty LLC | $14.01 | 2025 | Yupelri |
| Radius Health, INC. | $13.16 | 2021 | |
| Dexcom, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Ricker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.